

Solid Tumors Cancer

## A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

**Trial Status**

Active, not recruiting

**Trial Runs In**

14 Countries

**Trial Identifier**

NCT03448042 GO40311

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

**Genentech, Inc.**

Sponsor

**Phase 1**

Phase

---

**NCT03448042 GO40311**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>= 18 Years

**Healthy Volunteers**

No

---